LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Strona główna・Stock List・Illumina Inc

Illumina Inc

Closed

SectorHealthcare

161.75 -0.62

Buy Sell

Overview

Share price change

24h

Current

Min

159.69

Max

163.5

Key metrics
By Trading Economics
Income	-200M 134M
Sales	-68M 1.1B
P/E Sector Avg	26.256 50.102
EPS	1.15
Profit margin	12.282
Employees	8,600
EBITDA	-144M 301M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-12.49% downside

Dividends
By Dow Jones
Next Earnings	30 lip 2026

Market Stats
By TradingEconomics
Market Cap	2.3B 22B
Previous open	162.37
Previous close	161.75

News Sentiment

By Acuity

41%

59%

122 / 344 Ranking in Healthcare

Illumina Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 cze 2026, 20:30 UTC

Earnings

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 cze 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 cze 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 cze 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 cze 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 cze 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 cze 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 cze 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 cze 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 cze 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 cze 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 cze 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 cze 2026, 21:00 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 cze 2026, 20:46 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 cze 2026, 20:38 UTC

Earnings

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 cze 2026, 20:21 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 cze 2026, 20:12 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Product Rev $594M

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Loss $177M >PANW

Peer Comparison

Price change

Illumina Inc Forecast

Price Target

By TipRanks

-12.49% downside

12 Months Forecast

Average 142.25 USD -12.49%

High 180 USD

Low 95 USD

Based on 12 Wall Street analysts offering 12 month price targets forIllumina Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Illumina Inc - Dist in the past 3 months.

Sentiment

By Acuity

122 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.